Elan and Wyeth Pharmaceuticals, a division of Wyeth, today announced that the United States Patent and Trademark Office recently issued Neuralab Limited, a wholly owned subsidiary of Elan, three patents for the companiesā joint research on immunotherapeutic approaches to the treatment of Alzheimerās disease.